Nutraplus commences commercial prod of anti-malarial drug

Drug maker Nutraplus India Ltd on Monday said it has commenced commercial production of anti-malarial drug ‘Lumefantrine’ in its new plant at Tarapur. In a filing to the Bombay Stock Exchange, Nutraplus India said, “The company has commenced commercial production in its new plant at Tarapur for anti-malarial drug LUMEFANTRINE.” Previously, it was engaged in the manufacturing of intermediate of the same drug (i.e. n-2 stage) at its existing factory and was selling to the various pharma companies. Now, the company is manufacturing the final end product (i.e. Lumefantrine) on full fledge basis at it’s new production facilities after obtaining necessary approvals, it added. Nutraplus further said that this is a forward integration and shall result in better margin. Moreover, the company is expected to achieve full production capacities in next 3 months in its plant, it said. Meanwhile, shares of the company were trading at Rs 416 apiece, up 6.10 per cent, from previous close on BSE at 15:25 hours.